Catatonia in neurodevelopmental disorders: assessing catatonic deterioration from baseline

Aaron J Hauptman1, David Cohen2, Dirk Dhossche3

  • 1Neurobehavioral Unit, Department of Psychiatry, Kennedy Krieger Institute, Baltimore, MD, USA; Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA.

The Lancet. Psychiatry
|January 28, 2023
PubMed

Insights

Diagnosing and managing catatonia in individuals with autism spectrum disorder presents challenges. This study proposes a novel measure to assess catatonia, differentiating it from underlying neurodevelopmental disorders.

Area of Science:

  • Neuropsychiatry
  • Developmental Neuroscience
  • Autism Spectrum Disorder Research

Background:

  • Catatonia is a specifier for autism spectrum disorder (ASD) in the DSM-5.
  • Clinical practice reveals diagnostic and management challenges for catatonia in patients with neurodevelopmental disorders, particularly ASD.
  • Existing diagnostic and treatment paradigms require refinement for this population.

Purpose of the Study:

  • To summarize current literature on catatonia in neurodevelopmental disorders, including ASD.
  • To outline concerns regarding the diagnosis and management of catatonia in this patient group.
  • To propose a novel conceptual framework and practical measure for diagnosing and monitoring catatonia in individuals with neurodevelopmental disorders.

Main Methods:

  • Literature review on catatonia in neurodevelopmental disorders.
  • Development of two novel concepts: 'personalized score at baseline' and 'catatonic deterioration from baseline'.
  • Proposal for a comprehensive measure considering motor, medical, functional, and neurobehavioral symptoms.

Main Results:

  • Current diagnostic and treatment approaches for catatonia in neurodevelopmental disorders are insufficient.
  • A need exists for a specialized measure to differentiate catatonia from underlying neurodevelopmental conditions.
  • The proposed concepts aim to provide a baseline estimate and assess deterioration due to catatonia.

Conclusions:

  • A new measure is needed to accurately diagnose and monitor catatonia in individuals with neurodevelopmental disorders.
  • The proposed 'personalized score at baseline' and 'catatonic deterioration from baseline' offer a novel approach.
  • This framework aims to support clinicians and researchers working with this underserved population.